Relsys International has launched Argus PV, the first adverse event reporting solution designed to promote Good Pharmacovigilance Practices. These practices are designed to effectively detect and alert the drug safety professional to new and potentially important information on drug-associated adverse reactions.
Argus PV, which incorporates QED Solutions’ Qscan technology, is a complete integrated solution that supports Good Pharmacovigilance Practices (GPVP) from enhanced tools to collect information at the front end, through proportional statistical data evaluation tools and a complete signal work-up and documented environment.
The product supports GPVP in a Web-based, validated environment that focuses on drug safety as a clinical art.
Argus PV was developed under a strategic agreement with RCN Associates and its principal, Dr Robert C Nelson, a 21-year veteran of the FDA. While with the FDA, Dr Nelson was the lead in the design, management and implementation of the Adverse Event Reporting System (AERS).
A framework for good pharmacovigilance practice combines both surveillance and reporting functions, said RCN Associates principal, Dr Robert C Nelson, in a media release. Argus PV addresses both functions and is a cost-effective cornerstone for a corporate drug safety risk management strategy.